Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDPieris Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$4.80 | -$4.80 | -$4.80 |
| Q2 2024 | 1 | -$2.40 | -$2.40 | -$2.40 |
| Q3 2024 | 1 | -$4.00 | -$4.00 | -$4.00 |
| Q4 2024 | 1 | -$4.80 | -$4.80 | -$4.80 |
Pieris Pharmaceuticals, Inc. Earnings Date And Information
Pieris Pharmaceuticals, Inc. last posted its earnings results on Wednesday, November 13th, 2024. The company reported $-2.19 earnings per share for the quarter, topping analysts' consensus estimates of $-4 by $1.81. The company had revenue of 0 for the quarter and had revenue of 42.81 M for the year. Pieris Pharmaceuticals, Inc. has generated $-22 earnings per share over the last year ($-21.8 diluted earnings per share) and currently has a price-to-earnings ratio of -1.13. Pieris Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 13th, 2024 based on prior year's report dates.
Pieris Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$4.00 | -$2.19 | 1.81 | $1.07 M | $0 |
| 08/14/2024 | Q2 2024 | -$2.76 | $2.24 M | $0 | ||
| 05/15/2024 | Q1 2024 | -$0.12 | -$3.95 | -3.83 | $53,000 | |
| 04/29/2024 | Q4 2023 | -$3.71 | $1.30 M | |||
| 11/14/2023 | Q3 2023 | -$8.80 | -$8.70 | 0.1 | $7.74 M | $19.52 M |
| 08/10/2023 | Q2 2023 | -$12.80 | $3.63 | 16.43 | $4.02 M | $20.06 M |
| 05/10/2023 | Q1 2023 | -$13.22 | $1.94 M | |||
| 03/31/2023 | Q4 2022 | -$8.68 | $5.85 M | |||
| 11/04/2022 | Q3 2022 | -$9.17 | $4.51 M | $5.37 M | ||
| 08/04/2022 | Q2 2022 | -$8.80 | -$0.14 | 8.66 | $10.47 M | $3.70 M |
| 05/11/2022 | Q1 2022 | -$9.60 | -$2.98 | 6.62 | $10.99 M | |
| 03/01/2022 | Q4 2021 | -$10.16 | $8.44 M | |||
| 11/02/2021 | Q3 2021 | -$19.20 | -$19.53 | -0.33 | $5.32 M | $4.06 M |
| 08/05/2021 | Q2 2021 | -$20.03 | $5.67 M | $3.29 M | ||
| 05/17/2021 | Q1 2021 | -$13.60 | -$5.93 | 7.67 | $15.63 M | |
| 03/31/2021 | Q4 2020 | -$20.57 | $1.88 M | |||
| 11/04/2020 | Q3 2020 | -$12.80 | -$21.03 | -8.23 | $11.72 M | $2.94 M |
| 08/10/2020 | Q2 2020 | -$14.40 | -$7.56 | 6.84 | $8.03 M | $11.25 M |
| 05/11/2020 | Q1 2020 | -$12.80 | -$5.21 | 7.59 | $13.26 M | |
| 03/13/2020 | Q4 2019 | -$20.00 | -$1.16 | 18.84 | $17.27 M |
Pieris Pharmaceuticals, Inc. Earnings: FAQ's
When is Pieris Pharmaceuticals, Inc.'s earnings date?
Pieris Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 13th, 2024 based off last year's report dates.
Did Pieris Pharmaceuticals, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Pieris Pharmaceuticals, Inc. (:PIRS) reported $-2.19 earnings per share (EPS) to beat the analysts' consensus estimate of $-4 by $1.81.
How can I listen to Pieris Pharmaceuticals, Inc.'s earnings conference
call?
The conference call for Pieris Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
How can I read Pieris Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Pieris Pharmaceuticals, Inc.'s latest earnings report can be read online.
How much revenue does Pieris Pharmaceuticals, Inc. generate each year?
Pieris Pharmaceuticals, Inc. (:PIRS) has a recorded annual revenue of $42.81 M.
How much profit does Pieris Pharmaceuticals, Inc. generate each year?
Pieris Pharmaceuticals, Inc. (:PIRS) has a recorded net income of $42.81 M. Pieris Pharmaceuticals, Inc. has generated $-21.8 earnings per share over the last four quarters.
What is Pieris Pharmaceuticals, Inc.'s price-to-earnings ratio?
Pieris Pharmaceuticals, Inc. (:PIRS) has a price-to-earnings ratio of -1.13 and price/earnings-to-growth ratio is -0.03.